Supplier News Breaks Archives
Moberg launches new formulation of Kerasal Nail
March 24th, 2014
STOCKHOLM, Sweden – Moberg Pharma AB this week plans to begin shipping a new patent-pending formulation of its Kerasal Nail fungal nail product to U.S. consumers.
The company said Monday that new product is shipped as a flow-through and will be available at all current Kerasal Nail retailers, including major drug chains CVS/pharmacy, Walgreens and Rite Aid; mass merchants such as Walmart and Target; and leading supermarket chains such as Publix and Safeway.
Retail distribution of Kerasal Nail in the United States encompasses more than 30,000 outlets. As of the end of last year, Kerasal Nail had 20% of the U.S. market share in the over-the-counter fungal nail category, according to Moberg.
The new formula provides benefits to consumers by improving user-friendliness, facilitating nail penetration and improving stability, the company said.
Moberg has applied for patent protection for the new product, with the patent for the new formula projected to expire in 2034.
"I am very pleased to announce the launch of the improved formula," stated Peter Wolpert, chief executive officer of Moberg Pharma AB. "The new and improved Kerasal Nail demonstrates the value of our development approach, which continues to deliver innovative products with unique benefits to consumers. The new patent application can provide long term IP [intellectual property] protection for our lead product."
The OTC portfolio of Moberg, which has offices in Stockholm and New Jersey, includes the brands Kerasal, Jointflex, Kerasal Nail Domeboro, Vanquish, Fergon and Kaprolac. Kerasal Nail (Nalox in many markets) is a leading product for the treatment of nail disorders in the U.S and Nordic markets.